|Biotech partner:||bioMérieux (France)|
|Pharma Partner:||GSK (UK)|
|Type of agreement:||* R&D
|Disease area:||metastatic melanoma|
|Nature of the agreement:||bioMérieux and GSK have signed an agreement to develop a novel molecular test for cancer.The two companies will develop a theranostic test to aid oncologists in choosing the appropriate treatment for metastatic melanoma.
The new assay is intended to detect mutations (beyond the conventional V600E form) in the
B-Raf gene. The assay will be used to test phase II and III metastatic melanoma patients to select those eligible for treatment with GSK's B-Raf or MEK inhibitor compounds.
bioMérieux and GSK will bring complementary expertise to the project. GSK will bring its extensive experience in oncology and clinical evaluation. Global R&D teams from bioMérieux will develop and seek regulatory approval of the test. An in vitro diagnostic kit will be commercialized worldwide, leveraging resources from bioMérieux and the collaboration. GSK and bioMérieux have a separate, ongoing collaboration to develop a test for breast cancer patient stratification since November 2009.
|Financial terms of the agreement:||Financial details were not disclosed.|